---
title: The ablation aficionados guide to CIRSE 2024
description: CIRSE 2024 Lisbon overview for Percutaneous Ablation aficionados - including everything CAS-One IR related
---

[CASCINATION News ](https://www.cascination.com/en/news)

# [The ablation aficionados guide to CIRSE 2024](https://www.cascination.com/en/news/ablation-aficionados-guide-to-cirse-2024)

 Written by [Ted Farwell](https://www.cascination.com/en/news/author/ted-farwell) | Aug 10, 2024 12:31:34 AM

CIRSE is a large, comprehensive 4.5 day event. While topics covering Interventional Oncology are not typically the main focus, they are still very present. The CAS-One IR team will also be very present, and we highlight below, what we believe is most relevant for ablation aficionados.

In our heavily-biased opinion, the most exciting event at CIRSE 2024 is the launch of CAS-One IR 4.2 software. This new release brings many new things, but the major features are a lesion-based workflow, enhanced multi-needle capabilities, a reablation workflow, and an even more powerful AI-Driven AblaSure. [You can see our landing page for more details](https://www.cascination.com/cas-one-ir-4.2?hsLang=en)

At our booth you can see the new software, and also take part in this year’s CAS-One IR AI Challenge. In the first edition, we had over 45 participants from 11 countries, over 5 congresses. The overall winner was Dr. Ádám Zoltán Farkas (Budapest, HU), who now has helped designed this years challenge. Come by and compete for a prize.

 

SPHAIRE is a new addition this year to the scientific agenda. A separate stage to speak about all things AI. CAS-One IR’s industry leading AI technology has been accepted for a podium presentation.

On Monday Sept. 16th, we are hosting our own scientific dinner and after party. At the beautiful Monte Mar restaurant, we have 3 speakers highlighting Kidney Ablation with CAS-One IR, the need for AI-Driven AblaSure, and other topics.

  

Three posters featuring CAS-One IR have also been accepted, including the first experience from over 100 tumors treated at MD Anderson in Houston, Texas:

[P-768 - Stereotactic navigated electrochemotherapy for a treatment of a non-resectable/non-thermal treatable liver metastasis](https://cirse-summit.meta-dcr.com/cirse2024poster/crs/stereotactic-navigated-electrochemotherapy-for-treatment-of-a-non-resectable-non-thermal-treatable-liver-metastasis?t=90&v=slides) - M. Doppler (Freiburg, DE)

[P-434 / Initial experience from stereotactic thermal ablation for liver tumors in a large academic center in the United States](https://cirse-summit.meta-dcr.com/cirse2024poster/crs/initial-experience-from-stereotactic-thermal-ablation-for-liver-tumors-in-a-large-academic-center-in-the-united-states?t=90&v=slides) - I.Paolucci / B. Odisio (Houston, USA) 

[P-745 / Microwave ablation of a HCC in a challenging location adjacent to the portal vein and inferior vena cava - V. Mayr](https://cirse-summit.meta-dcr.com/cirse2024poster/crs/microwave-ablation-of-a-hcc-in-a-challenging-location-adjacent-to-the-portal-vein-and-inferior-vena-cava?t=211&v=slides)  (Regensburg, DE) 

Finally, we will participate in one of the hands-on session, also indicated in the day-by day ablation-aficionado’s scientific agenda.

Now, for the complete scientific highlights:

**Saturday September 14th **

**FS 123 – HCC: open questions 10:00–11:00 **Auditorium 8** **

123.1 / BCLC or no BCLC? - A. Vitale

123.2 / When to stop downstaging HCC to transplant - E. Bozzi

**FS 133 – HCC: when one therapy is not enough **11:30–12:30 Room 5.A

133.2 / Ablation plus TACE: are we ready for standardization? - M. Burgmans

**WS 163 – Reliability in percutaneous tumour ablation **16:15–17:15 Room 5.B

163.2 / Predictive software for percutaneous ablations - B. Odisio

**SP 177 – Ablation of kidney tumors: techniques and outcomes **17:30–18:30 Room 3.B

177.1 / SAFE final results: prospective evaluation of robotic-assisted percutaneous abdominal thermal ablation - B. Bonnet

177.2 / Thermal ablation of renal tumors: a first robotic-assisted series - C. Pernet

177.3 / A retrospective analysis of achieving "Trifecta" outcomes in percutaneous cryoablation of T1b renal masses in 50 patients. A 4 year single center experience - E. Petsatodis

177.4 / MulticentRe rEal World outcomes of IrReversible Electroporation for small kiDney cancers (REWIRED) - V. Chan

177.5 / Comparison between microwave vs. radiofrequency ablation for small renal masses: perioperative and oncological outcomes - C. Pizzi

177.6 / Outcomes of renal function following thermal ablation of renal cell carcinoma -M. Moreton-Smith

177.7 / Percutaneous microwave ablation of complex cystic renal masses- R. Arellano

 

**Sunday September 15th**

**CEC 212 – Cholangiocarcinoma **08:30–09:30 Room 5.A

212.1 / Current systemic treatments for non-resectable cholangiocarcinoma - M. Machado

212.2 / Local treatments for perihilar cholangiocarcinoma -O. van Delden

212.3 / Percutaneous ablation for intrahepatic cholangiocarcinoma - U. Pua

212.6 / The role of locoregional therapies in the first line - M. Burgmans

**FS 222 – New developments in IO **10:00–11:00 Auditorium 6

222.2 / Thermochemical ablation - E. Cressman

222.3 / Histotripsy - M. Mendiratta-lala

**SP 266 – Ablation of metastatic CRC and liver tumors: techniques and outcomes **16:15–17:15 Auditorium 6

266.1 / Registration accuracy of deformable image registration methods for quantification of minimum ablation margin during image-guided liver ablations - a comparative study - J. Hong

266.2 / Optimization of colorectal liver metastases ablation through real-time metabolic imaging stereotactic margin assessment and confirmatory biopsies; allowing for immediate retreatment: a single-center prospective study - P. Dimopoylos

266.3 / Electrochemotherapy of peri-hilar liver tumors : long time follow-up from a single institution case series - L. Tarantino

266.4 / Preliminary results of real time monitored IRE device for liver ablation: a single center cohort - P. Beunon

266.5 / Microwave ablation of colorectal pulmonary metastases offers excellent local tumor control and prolongs time off chemotherapy - V. Sotirchos

266.6 / Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): a randomized, international, multicenter, phase III trial - M. Meijerink

266.7 / Local treatment of colorectal liver metastases in the presence of extrahepatic disease: survival outcomes from the Amsterdam Colorectal Liver Met Registry (AmCORE) - H. Schulz

**SP 275 – Bone, spine and soft tissues **17:30–18:30 Room 1.15

275.3 / Safety and efficacy of electrochemotherapy for the treatment of metastatic bone disease - N. Papalexis

275.4 / Dynamic contrast-enhanced MRI in patients with suspected osteoidosteoma undergoing CT-guided radiofrequency ablation - G. Pöhler

 

**Monday September 16th**

**CEC 313 – MSK IO: what's new - 8:30-9:30 Auditorium 8 **

313.1 / Heat-based thermal ablation of osseous malignancy -C. Pusceddu

313.2 / Cryoablation of musculoskeletal tumours - G. Tsoumakidou

313.3 / Electrochemotherapy in the spine - F. Deschamps

313.4 / Extraspinal electrochemotherapy - R. Cazzato

313.6 / Techniques to avoid complications - A. Kelekis

** ****SPH 327 – Current AI applications in interventional radiology - 10:00-11:00 SPHAIRE Stage**

SPH 327.5 / Leading the future of interventional oncology: innovations in stereotactic CT-guided tumor ablation – B. Eigl

**FS 331 – Recent epidemiological trends in HCC and iCC: implications for treatment 11:30-12:30 Auditorium 8**

331.1 / Global epidemiological trends - S. Khan

331.2 / Ablation versus surgery: the start of a new debate? - R. Iezzi

**CEC 363 – Renal cell carcinoma **16:15–17:15 Auditorium 7

363.1 / What do the guidelines tell us? - C. Georgiades

363.2 / Biopsy: when and how

363.3 / Robot-assisted partial nephrectomy - F. Villacampa

363.4 / Percutaneous ablation for T1a - M. Krokidis

363.5 / Percutaneous ablation for T1b - T. Wah

363.6 / Registries and trials - P. Laeseke

**CBD 323 – MSK IO: challenging cases **10:00–11:00 Room 5.A

323.1 / Spine augmentation - S. Marcia

323.2 / Spine ablation - J. Jennings

323.3 / Peripheral skeleton ablation - R. Cazzato

323.4 / Desmoid - M. Ahmed

**HDT-TA 36.4 – Tumour ablation: Planning, robotics, monitoring and assessment for ablation - **16:15–17:45 (Europe/Lisbon)** **

Come see innovative devices, including CAS-One IR for a more comprehensive overview

**CBD 373 – Challenging ablation in renal cell carcinoma **17:30–18:30 Room 5.B

373.1 / Challenging locations: upper renal pole - G. Carrafiello

373.2 / Challenging locations: central endophytic - R. Arellano

373.3 / Solitary kidney - D. Filippiadis

373.4 / Chronic renal disease - C. Georgiades

 

**Tuesday Sept 17th **

**CEC 413 – CRC liver metastatic disease - **8:30–9:30 Auditorium 8

           413.4 / Stereotactic ablation - R. Bale

          413.6 / Resectability and ablatability criteria - M. Meijerink

**FS 423 – Local treatments for pancreatic cancer - **10:00–11:00 (Europe/Lisbon)** -**Auditorium 8

423.1 / Pulsed electrical fields - R. Inchingolo

423.2 / Thermal ablation - K. van Lienden

**CEC 433 – Building an ablation practice - **11:30–12:30 Auditorium 8

433.1 / Thyroid - B. Çekiç

433.2 / Breast - E. de Kerviler

433.3 / Lung - D. Dupuy

433.4 / Pancreas - G. Narayanan

433.5 / RCC - S. Solomon

433.6 / Prostate - V. Ramalingam

433.7 / Panel discussion

**FS 435 – Artificial intelligence for interventional radiology **11:30–12:30 Room 5.A

435.1 / AI basics: what the IR should know - B. Meyer

435.2 / Radiomics 2.0: how to increase clinical translation in IR settings - N. Papanikolaou

435.3 / AI in patient selection and treatment planning in interventional radiology - J. Chapiro

435.4 / AI in clinical and imaging follow-up in interventional radiology - F. Gómez Muñoz

** **

**Wednesday September 18th **

**CBD 512 – Complications and follow-up imaging after percutaneous ablation - **8:30–9:30 Auditorium 8

512.1 / After lung ablation - A. Najafi

512.2 / After liver ablation - C. Sofocleous

512.3 / After kidney ablation - P. Torcia

512.4 / After bone and soft-tissue ablation - A. Kurup

 

[View full post](https://www.cascination.com/en/news/ablation-aficionados-guide-to-cirse-2024)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Ted Farwell"
  },
  "dateModified" : "2024-09-05T13:35:57.008Z",
  "datePublished" : "2024-08-10T00:31:34Z",
  "headline" : "The ablation aficionados guide to CIRSE 2024",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1254,
    "url" : "https://4661825.fs1.hubspotusercontent-na1.net/hubfs/4661825/CIRSE%202024%20Lisbon%20Portugal-Thumbnail.png",
    "width" : 2400
  },
  "mainEntityOfPage" : "https://www.cascination.com/en/news/ablation-aficionados-guide-to-cirse-2024",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News"
  }
}
```